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 Abstract 
 
Punctate Inner Choroidopathy (PIC), an idiopathic inflammatory multifocal 
chorioretinopathy that predominantly affects young myopic women, appears to 
be relatively  rare, but there is limited data to support accurate estimates of 
prevalence, and it is likely that the condition is under-diagnosed. The etiological 
relationship between PIC and other conditions within the ‘white dot syndromes’ 
group remains uncertain. We, like others, would suggest that PIC and multifocal 
choroiditis with panuveitis (MCP) represent a single disease process that is 
modified by host factors (including host immunoregulation) to cause the range of 
clinical phenotypes seen.   The impact of PIC on the patient is highly variable, 
with outcome ranging from complete spontaneous recovery to bilateral severe 
sight-loss. Detection and monitoring has been greatly facilitated by modern 
scanning techniques, especially OCT and autofluorescence imaging, and may be 
enhanced by co-registration of sequential images to detect change over time. 
Depending on the course of disease and nature of complications, appropriate 
treatment may range from observation to systemic immunosuppression and anti-
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angiogenic therapies. PIC is a challenging condition where treatment has to be 
tailored to the patient’s individual circumstances, the extent of disease, and the 
risk of progression. 
 
 
Keywords 
Punctate inner choroidopathy, choroidal neovascularization, posterior uveitis, 
white dot syndromes. 
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I. Introduction 
 
• Definition 
 
Punctate inner choroidopathy (PIC) is a relatively rare idiopathic inflammatory 
multifocal chorioretinopathy that most commonly affects young myopic women. 
Most of these lesions involve the posterior pole, arising at the level of the retinal 
pigment epithelium (RPE) and inner choroid in the absence of anterior chamber 
or vitreous inflammation (86). Although it may be self-limiting with a favorable 
outcome, inflammation or neovascularization abutting the fovea may cause 
permanent visual loss. Depending on the course of disease and development of 
complications, treatment may range from observation to systemic 
immunosuppression and intravitreal anti-angiogenic therapies. 
• Historical background 
PIC was first described by Watzke et al. in 1984 in a series of 10 young, 
otherwise healthy, myopic women who presented with blurred central vision, 
photopsia and paracentral scotomas, and had well circumscribed yellow-grey 
lesions at the level of the inner choroid and retinal pigment epithelium associated 
with small neurosensory retinal detachments in the macula in the absence of 
detectable intraocular inflammation.(86) Eight out of the 10 patients presented 
with bilateral lesions, and six developed choroidal neovascularization (CNV).  
Although initially hypothesized to be secondary to myopia, the episodic nature of 
recurrences was subsequently acknowledged to be more suggestive of an 
underlying inflammatory pathogenesis.(1)  
 
• Other names 
Punctate inner choroiditis, multifocal inner choroditis 
 
II. Epidemiology and Demographics 
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PIC is a relatively rare multifocal chorioretinopathy. It is difficult to make an 
accurate estimate of the incidence and prevalence of PIC for a number of 
reasons: first, there is a wide range of presentation and severity, such that 
many cases may remain unrecognized; second, there is uncertainty over 
its classification, notably whether it is a distinct entity from multifocal 
choroiditis with panuveitis (MCP) or part of the same spectrum; and third, 
in the absence of national registries or reporting systems, estimates are 
often based on data from single centers for which the size of population 
and completeness of coverage is uncertain. There is also variable practice 
between institutions as to whether patients with PIC are under of the care 
of uveitis subspecialists, medical retina subspecialists, or both, such that 
estimates drawn from a ‘single service’ cohort may be an underestimate. 
(1, 8, 25, 35) 
 
While acknowledging these limitations, the following estimates may still be 
helpful. A retrospective review at the University of Iowa by Brown et al 
collected 16 cases of PIC over a period of 15 years (1980 to 1994). Based 
on an estimate of the population of Iowa of 2.8 million, this would equate to 
around 0.4 new cases per million population per year.(10) A study in the 
United Kingdom by Jones reporting the case-mix of the Manchester Uveitis 
Clinic from 1991 to 2013 found that PIC accounted for 2.8% of all uveitis 
cases referred to that service. They noted that the incidence of new cases 
seen from their local catchment area was 5.6/100 000/year for the decade 
2003-2013.(35) Based on these figures, an incidence of around 1.6 per 
million population per year may be estimated. This figure,  however,  may 
be an over-estimate owing to higher rates of ‘out-of-area’ referrals for 
complex conditions such as PIC compared to more common forms of 
uveitis.  
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Gerstenblith et al. evaluated the demographics and clinical features of PIC 
by analyzing a survey questionnaire completed by 77 patients through the 
PIC Society.(30) Among the respondents, 90% were female, 97% were 
Caucasian, and 85% were myopic with a median refractive error of  
-7.00 diopters in each eye. The majority of the participants were young, 
with a median age of 30 years (range, 15-55).  
As noted in the Gerstenblith study, PIC tends to mostly affect young 
women. Other series confirm this profile, with females comprising 92 - 
100% in the USA (10, 62,86), 76-93% in the UK (25,35), and 72% in China 
(89). Similarly myopes predominate in all countries studied. Myopia was 
reported in 80-100% of series from the US, the UK and China. In their 
series of 136 UK patients with PIC, Essex et al. (25) reported that the 
mean spherical equivalent refraction was -4.6 diopters with a range of -14 
to +4 diopters. Additionally Reddy et al. noted that patients with PIC had 
the highest level of myopia of all inflammatory chorioretinopathies. (67) 
 
There is, however, a risk of selection and reporting bias here. Since 
diagnosis is based on subjective assessment of a clinical pattern rather 
than a diagnostic test based on etiology, it is likely that clinicians will be 
more likely to diagnose the condition when seen in a typical patient, and 
thus the same clinical pattern in an older, male, hyperopic patient may be 
labeled with an alternative diagnosis (such as ‘idiopathic’, or multifocal 
choroiditis); this may be exaggerated in surveys of patient societies (such 
as the Gerstenblith study) where clinician bias may be compounded by 
patient self-reporting bias. Certainly PIC is not exclusive to the young, 
female, myopic population as shown in a number of series and case-
reports. (89, 10, 35, 30, 7) 
 
III. Pathogenesis 
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The etiology of PIC is unknown, and its pathogenesis poorly understood. In 
common with the other inflammatory conditions that have been lumped 
together as ‘white dot syndromes’, it is proposed to be an autoimmune 
disease that arises in the context of polygenic susceptibility triggered by an 
environmental stimulus, such as infection, immunization, or stress. In the 
context of PIC, a plausible mechanism should ideally also explain the 
preponderance (but not exclusivity) of the female myopic phenotype.  
 
A further challenge is to know whether PIC is truly a distinct disease with its 
own etiology and pathogenesis or simply a subset of a larger condition (e.g. 
a putative ‘PIC/MCP spectrum’). (34) With regard to the latter hypothesis, 
additional questions arise. First, what are the boundaries of this condition, i.e. 
which other clinical ‘white dot syndromes’ should be included? Second, if 
this spectrum is indeed a single condition arising from a common etiology 
and pathogenesis, do the variations in the clinical phenotype between 
syndromes arise due to modification of the shared disease process by 
‘modifiers’ such as gender and degree of myopia? 
 
Jampol and Becker suggest that, like many autoimmune inflammatory 
diseases, an unknown insult may trigger an autoimmune response against 
antigens in outer retina or inner choroid, leading to the development of 
PIC.(34) A genetic influence is probable, not through a strong Major 
Histocompatibility Complex (MHC) association such as seen in birdshot 
chorioretinopathy, but through the combined effect of multiple genes relevant 
to immunoregulation, the effect of which is likely to be to increase the risk of 
autoimmune diseases generally. Family history of autoimmune disease is 
common in PIC, reported in 26% by the Gerstenblith study. (30) Personal 
history of autoimmune disease varies between 3-13% (2). There has also 
been one case report of PIC in a mother and daughter (80).   
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Targeted genotyping in a small study of 31 PIC patients and 30 MCP 
patients by Atan et al. demonstrated that PIC and MCP shared an 
association with a specific IL10 haploptype which included two haplotype-
tagged small nucleotide polymorphisms (htSNPs) that in a previous study 
were associated with a larger group of 192 non-infectious uveitis 
patients.(2,3) The risk-conferring alleles were IL10htSNP2A (associated with 
low IL-10 production) and IL10htSNP5T (functional significance uncertain). 
No positive associations were seen with any TNF haplotypes, although one 
TNF haplotype was weakly negatively associated with the PIC/MCP group. 
Severity of disease was not associated with any haplotypes. (2) Atan et al. 
also investigated possible linkage with the MHC molecules HLA-B7 and 
HLA-DR2 which have been linked to the clinically similar condition, POHS. 
HLA-B7 was not associated with MCP or PIC (55), but there was an 
increased frequency of the HLA-DRB1*15 allele (HLA-DR2) in PIC patients 
compared to controls (26% vs. 16%).(2) 
 
Histopathological studies are limited as tissue is generally restricted to 
excised subfoveal CNV, but analysis does support the involvement of the 
immune system. In a study of 6 eyes with PIC, Olsen et al showed that the 
CNV was usually a type 2 membrane occurring between the neurosensory 
retina and the RPE layer.(59) Findings included a stalk connecting the base 
of the neovascular membrane to the choroid, presence of endothelium-lined 
vascular channels, pericytes, fibrocytes, RPE cells, collagen fibrils and 
variable amounts of inflammatory cell aggregate, mainly lymphocytes and 
plasma cells. This study proposed five stages in the development of CNV in 
PIC developing from a focal inflammatory injury to Bruch membrane (stage 
1), early neovascularization through a break in Bruch membrane into the 
subretinal space (stage 2), coalescence of neovascular foci (stage 3), 
subretinal fibrosis with contraction and bleeding (stage 4) and cicatrization 
resulting in a fibrotic plaque with loss of RPE and photoreceptors (stage 
5).(59) In a study comparing excised CNV from six PIC vs. eight MCP 
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patients, Shimada et al. reported expression of VEGF and CD68 
(macrophage/microglia marker) on CNV in both conditions, but detection of 
lymphocytes was limited to CD20+ cells (B cells) in three MCP CNV (no PIC 
CNV) and no CD3+ cells (T cells) in any CNV.(75) 
 
Recent progress in understanding the disease process,if not the etiology, 
comes from imaging techniques such as OCT which can catalogue the 
progression of inflammatory PIC lesions. Based on these studies, Zhang et 
al. propose the following model: the photoreceptor layer is the primary target 
of the disease; the elevation of the RPE seen in the early stages represents 
recruitment and infiltration of inflammatory cells to form an inflammatory 
nodule; the nodule breaks through the RPE and destroys the overlying 
photoreceptors.Then the nodule regresses, revealing the choroidal 
component of the lesion and causing herniation of the retinal layers through 
the break in Bruch membrane, and RPE proliferation repairs the RPE break, 
but the photoreceptor defects remain.(90) 
 
A number of studies have shown that the choroidal thickness increases 
during active PIC (31,90). Additionally Hirooka et al. report that treatment in 
a patient with active PIC led to an increase in choroidal blood flow velocity 
(and decrease in choroidal thickness). This finding was replicated during a 
further episode of recurrence in the same patient.(31) It is not yet clear, 
however, where this apparent impairment of choroidal circulation during 
active PIC fits into the disease process. 
 
A high proportion of patients with PIC are myopic (3,25, 89), and it was originally 
proposed that the lesions were secondary to myopia and possibly represented “a 
lacquer-crack type of chorioretinal scar”.(86) Although the pathogenesis is now 
thought to be immune-mediated, the link to myopia still requires consideration. 
As discussed earlier all significant series demonstrate the myopic phenotype, 
and comparative studies suggest that the degree of myopia is higher than in 
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other ‘white dot syndromes’.(67) The advent of spectral domain optical 
coherence tomography (SD-OCT) has demonstrated that Bruch membrane is 
intact in the early phase of PIC lesion development and that disruption appears 
to be a consequence, rather than a cause, of the inflammatory lesions.(15,90) 
Although this argues against myopic cracks being a major contributor to the 
disease process, it is possible that myopic thinning and/or increased fragility of 
the Bruch membrane/RPE complex does allow greater immune trafficking and 
facilitation of neovascularization; ultra high-resolution OCT may in the future 
reveal whether this is facilitated by ‘micro-cracks’ in the Bruch’s membrane/RPE 
complex. Zhang et al offer two further possibilities: that PIC results from an 
infection in the photoreceptors facilitated by the myopic anatomy or that there is 
cross-reactivity between an infectious agent and innate retinal components 
associated with myopia.(90) 
 
 
IV. Clinical description  
 
According to the survey by Gerstenblith et al., initial symptoms in PIC are 
most commonly scotoma (91%), blurred vision (86%), photopsia (73%), 
floaters (69%), photophobia (69%), and metamorphopsia (65%). Loss of 
peripheral vision was reported in 26% of patients.(30) These symptoms may 
fluctuate in severity, with 32% reporting symptoms waxing and waning prior 
to commencing treatment. Visual acuity at presentation is variable, reflecting 
the variable location of inflammatory lesions or their complications. Watzke 
et al reported that 8/12 eyes had VA of 20/50 or better, but that 2/12 eyes 
had VA of 20/500 or worse.(86) Reddy, Brown and colleagues report on one 
series of 16 patients with PIC in which over 75% of 30 involved eyes had VA 
better than 20/40 at presentation, and this was maintained over a follow-up 
period of 51 months.(10,67) In a larger series Essex et al. reported that of 74 
eyes with PIC lesions (but no CNV) at baseline the mean VA was 0.12 
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LogMAR at presentation falling to 0.24 LogMAR after a mean follow-up of 
4.5 years (20/26 and 20/35 Snellen equivalent respectively).(23) 
 
Fundoscopic features of PIC include small (100-300 microns), well-defined, 
yellow-grey spots (12-25 in number) normally limited to the posterior pole 
and distributed in a random (or rarely, linear) pattern. These inflammatory 
lesions occur at the level of the outer retina, RPE and inner choroid and may 
be associated with an overlying neurosensory detachment. They spare the 
peripapillary region (1, 25, 82, 86). In line with the original description by 
Watzke, typically PIC is not associated with signs of intraocular inflammation 
elsewhere in the eye. (86)  
 
It is perhaps the next phase that is the most critical to long-term visual 
prognosis. In some cases the inflammatory PIC lesions tend to resolve 
within a few weeks (1,23).   This is the best outcome, with lesions fading and 
full symptomatic visual recovery. Although complete resolution of lesions is 
reported (particularly in older studies), our experience is that in general 
these lesions still cause permanent structural changes which may be 
detected on multimodal imaging (particularly high-resolution OCT and 
autofluorescence) even after complete clinical resolution.  
 
An alternative, more common, outcome is the development of atrophic 
chorioretinal scars at the sites of previous inflammation. Over time these 
scars may become increasingly well-defined (‘punched out’), and may 
become pigmented.(1) Even in the absence of any on-going inflammation, 
our experience is that these scars may gradually increase in size, leading to 
worsening symptoms over time. This scar creep can lead to quite a profound 
impact on visual acuity if it arises in lesions abutting the fovea. 
 
Two further important complications may arise in a proportion of patients, 
both of which may significantly impact vision: choroidal neovascular 
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membranes (CNV) and subretinal fibrosis. CNV is associated with worse 
visual outcome. In the Brown series 5 out of 7 eyes with VA worse than 
20/200 had developed CNV.(10) The risk of CNV arising in PIC varies 
significantly between studies. The survey by Gerstenblith et al. found that 
69% percent of PIC patients reported that they had been diagnosed with 
CNV, most commonly within the first year.(30) Brown et al. reported CNV 
in 40% of eyes affected with PIC.(10) Essex et al. reported that in a cohort 
of 74 eyes with PIC lesions, but no CNV at baseline and a mean follow-up 
of 4.5 years, CNV developed in 22%.(25)  More recent studies are 
generally reporting lower rates of CNV. This may simply reflect differences 
in study design, sample acquisition, and length of follow-up, but it is 
interesting to speculate as to whether this could be a real effect arising 
from higher rates of immunosuppression and disease control in this cohort. 
Leung et al. noted an incidence rate of 0.02/eye-year (EY) for new CNV in 
their cohort. (44) Subretinal fibrosis is relatively common, with 56% of 
patients that developed subretinal fibrosis in at least one eye in the 
Gerstenblith study. (30) Over time certain patterns of fibrosis may be seen 
including peripapillary (‘napkin ring’ appearance) and ‘bridging’ fibrosis 
between scars. (12) 
 
Although most patients present with unilateral symptoms, the condition is 
commonly bilateral.  88% of patients had bilateral disease in the Brown 
series and 80% in the Watzke series.(10,86) Interestingly, however, more 
recent studies have reported more unilateral disease. Zhang noted only 
49% bilateral disease in a series from China (89), and in a series of 136 
patients from Moorfields Eye Hospital (UK), 54% had bilateral disease at 
presentation, increasing to 58% during the period of follow-up (mean 
follow-up of 6.2 years)(25). The Gerstenblith survey did not specifically 
report on the presence of bilateral disease, but did report that around one 
third of those who developed either CNV or subretinal fibrosis in one eye 
developed the same complication in the other eye.(30) 
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V. Diagnosis 
• Ancillary tests 
Investigations used in diagnosing and monitoring PIC have mainly included 
fluorescein angiography (FA), indocyanine green angiography (ICG) and 
optical coherence tomography (OCT) although newer modalities like fundus 
autofluorescence (FAF) imaging and OCT angiography are proving useful. 
(32,38, 51,79,87,90) 
 
The arteriovenous phase of FA shows punctate hyperfluorescent choroidal 
lesions with or without CNV. Areas of hyperfluorescence corresponding to 
the lesions will continue to persist through the early and late venous phase. 
Presence of CNV is demonstrated as a zone of hypofluorescence 
surrounding an area of hyperfluorescence in the early venous phase 
associated with leakage in the late phase.(1,46,59,82,89) 
 
ICG reveals hypofluorescent areas at the choroidal level in both early and 
late phases corresponding to the choroidal lesions that presumably 
represent localized areas of hypoperfusion.(46,82) ICG also demonstrates 
involvement of choriocapillaris with dilated choroidal capillaries seen around 
the PIC lesions (89). Hyperfluorescence of larger choroidal vessels 
resembling aneurysmal-like dilatations and vasculitis of the choriocapillaris 
have also been described (18). 
 
Channa et al evaluated the SD-OCT findings of patients with PIC and no 
CNV.(15) Clinically active patients demonstrated lesions with RPE elevation 
that fluctuated with disease activity and sub-RPE hyper-reflective signals 
with intact Bruch membrane. Photoreceptor-associated bands were not 
visible during active disease, but returned to normal visibility when lesions 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
were clinically stable. This may help in monitoring clinical activity of this 
condition.  
 
Zhang et al also studied the progression of PIC lesions using SD-OCT, 
concluding that the OCT findings vary depending on the stage of the disease 
activity.(90) In stage 1 there was minimal irregularity in the outer nuclear 
layer. In stage 2 the lesion is represented by a focal hyperreflective elevation 
of the RPE with corresponding disruption of the inner and outer segments of 
the photoreceptor interface. In stage 3 the lesions break through the RPE, 
forming a hump-shaped chorioretinal nodule with reflectivity beneath the 
outer plexiform layer (OPL). This may be associated with subsequent 
disruption of Bruch's membrane. During stage 4 lesions regress in a 
retrograde manner with tissue loss from the photoreceptor layer and inner 
choroid. This will result in a V-shaped hernia of the OPL and inner retina into 
the choroid – this is sometimes seen as “focal choroidal excavation”. (39) In 
stage 5 there is loss of photoreceptors around the lesion. This is often seen 
as extensive attenuation of the external limiting membrane, photoreceptor 
ellipsoid and interdigitation zones, adjacent to the PIC lesions.(57) 
 
Spaide et al. have also observed that some of the solid conical RPE elevations 
appear to rupture, resulting in an outpouring of infiltrate into the outer retina.(79) 
They point out that, even with multimodal imaging, the differentiation between 
active inflammatory lesions and CNV may not be possible because both can 
cause infiltrative lesions with breakdown in the blood–retina barrier. This is an 
important issue as optimal treatment depends on correct differentiation between 
inflammatory and neovascular PIC lesions. The use of OCT angiography to PIC 
lesions may enable differentiation between active inflammatory lesions and CNV. 
(38)  Levison et al conducted OCTA in 12 patients with PIC, and noted that 
OCTA was able to demonstrate the presence of a CNV in 11 patients, including 
all those in whom FFA had been inconclusive. (45) 
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Zarranz-Ventura et al. have described enhanced depth imaging OCT (EDI-
OCT) findings in clinically inactive PIC.(87) 46.6% of these lesions showed 
focal atrophy of the outer retina and RPE; 34.4% showed sub-RPE 
hyperreflective deposits while 68.5% had focal hyperreflective dots in the 
inner choroid; 18.8% showed localized RPE elevation with an underlying 
hyporeflective space. This last finding has been previously described as a 
sign of activity and therefore the authors suggest that it may represent 
subclinical PIC.(15, 84, 87) Choroidal thickness can be used to monitor the 
stage of disease activity.(84) Choroidal thickness increases throughout the 
active phase and reaches a peak during stage 3, then significantly 
decreases at later stages due to atrophy of outer retinal layers, reaching a 
minimum that was lower than the initial value at stage 1.(84,90)The use of 
serial quantitative assessment of retinal thickness maps on SD-OCT to 
detect flare-up of PIC lesions and monitor response to treatment has also 
been described.(51) 
 
FAF imaging in PIC has been described as showing active PIC lesions to be 
hypoautofluorescent spots with a hyperautofluorescent margin that fades as 
the lesions regress. Atrophic PIC lesions appear to be hypoautofluorescent. 
Subclinical lesions were hypofluorescent, but more distinctive on near 
infrared FAF imaging than on blue FAF imaging.(48) Photoreceptor 
attenuation around PIC lesions may be seen as zonal regions of 
hyperautofluorescence around the lesions, with corresponding visual field 
defects.(57) Semi-automated area-mapping software can been used in 
conjunction with FAF to monitor progression of lesion size, as demonstrated 
in a series of 22 eyes with PIC and 21 eyes of diabetic patients with 
photocoagulation scars, in which the PIC lesions were seen to progress at 
3.7mm2 per year vs. 0.13mm2 per year for the laser scars.(32) 
 
  
• Differential diagnoses  
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PIC is grouped as one of the ‘white dot syndromes’ and therefore the 
differential diagnoses include multifocal choroiditis and panuveitis (MCP), 
presumed ocular histoplasmosis syndrome (POHS), progressive Subretinal 
Fibrosis and Uveitis Syndrome (PSFU), Acute Posterior Multifocal placoid 
pigment epitheliopathy (APMPPE), birdshot chorioretinopathy (BCR) and 
multiple evanescent white dot syndrome (MEWDS), although we would 
argue that at least PIC and MCP form part of a spectrum of  the same 
condition.(24) As distinctions are frequently made between these syndromes, 
however, we highlight some of the classical clinical differences below. 
 
MCP resembles PIC but is characterized by the presence of significant 
vitritis with or without anterior chamber inflammation in association with 
typical fundal lesions. Clinically MCP runs a chronic and relapsing course 
with poorer visual prognosis, while PIC can be recurrent with intervening 
remissions.(37) Both conditions are known to more commonly affect young 
myopic women. The lesions characteristically result in yellow, punched-out 
atrophic scars and are associated with a high propensity for CNV. MCP can 
additionally be complicated by macular edema, epiretinal membrane, and 
optic neuropathy. CMO has been described in PIC but is rare.(2,37) We, like 
a number of investigators, would argue that that PIC and MCP are 
manifestations of the same disease, based on their overlapping clinical 
phenotype, similarities on multimodal imaging and even genotypic 
concordance.(2, 34) 
 
POHS is characterized by a triad of atrophic choroidal scars at the macula 
and mid-periphery, peripapillary atrophy, and CNV in the absence of 
aqueous or vitreous inflammation.(18,65) It is reported to be associated with 
HLA B7 and HLA DR2 and has a high incidence in Histoplasma-endemic 
regions.(18,65) While the association of Histoplasma with this distinctive 
phenotype would suggest true POHS (61), we would argue that many 
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superficially similar cases in non-endemic regions which are sometimes 
termed ‘pseudo-POHS’ are better considered as part of the PIC/MCP 
spectrum, rather than as a separate condition. 
 
PSFU (also known as diffuse subretinal fibrosis syndrome, DSFS) also 
affects young myopic women and starts as multiple, small, whitish-yellow 
RPE or choroidal lesions in the posterior pole and midperiphery that 
progressively coalesce and form large areas of subretinal fibrosis.(1,36) This 
entity carries a significantly worse prognosis than PIC.(36) In line with the 
previous discussion, we would propose that this is likely to form part of the 
PIC/MCP spectrum, but that the unusual phenotype is the result of the 
condition arising in individuals primed to develop a strongly pro-fibrotic 
response. 
 
The remaining conditions considered here do have clear differences from 
the PIC/MCP spectrum, although in most cases their etiology is equally 
poorly understood. APMPPE can be differentiated from PIC by the level and 
size of the lesions. In APMPPE lesions are slightly more superficial; they 
often form plaque-like lesions that are larger than PIC lesions, but carry a 
good prognosis. On early phases of FA, APMPPE shows characteristic 
hypofluorescence of the lesions, whereas in PIC lesions tend to be 
hyperfluorescent.(77)  
 
MEWDS presents with unilateral small grey-white lesions at the level of 
RPE/ retinal photoreceptors at the posterior pole, in the perifoveal and 
peripapillary regions. Unlike PIC lesions, these usually resolve without 
leaving scars or leading to CNV.(4,77) 
 
Reddy et al. noted that although enlarged blind spots are a feature of PIC, 
MCP, DSF and MEWDS other clinical, angiographic, and 
electroretinographic evidence suggest that these are different entities. 
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(67)Studies have shown some overlap between acute zonal occult outer 
retinopathy (AZOOR) and the ‘white dot syndromes’ with AZOOR being 
diagnosed in eyes with a previous diagnosis of PIC and MEWDS.(28) 
Typical abnormal electrodiagnostic findings in AZOOR, however, help to 
distinguish it from PIC. (67) 
 
BCR presents with midperipheral and peripheral pale yellow spots at the 
level of RPE/choriocapillaris. Although the aqueous is typically quiet, unlike 
PIC, BCR is associated with vitritis, retinal periphlebitis, vascular leakage, 
optic disc swelling, and macular edema and is strongly associated with HLA-
A29. (56,73,74) 
 
 
VI. Management  
 
The management of PIC is challenging for a number of reasons. First, the 
variable severity of disease between patients (or even in the same patient at 
different times) may mean that optimal treatment may appropriately range from 
observation to intensive immunosuppression and/or intravitreal anti-VEGF 
therapy. Second, any treatment strategy should distinguish between the major 
causes of sight loss in PIC. In pathogenetic terms, new or worsening PIC lesions 
are likely to reflect active inflammation, whereas a new neovascular membrane 
may not be a sign of active inflammation, but certainly is a sign of an active 
neovascular drive. Third, the decision as to whether a patient is likely to benefit 
from maintenance therapy is difficult because of the need to balance the variable 
prognosis of patients with PIC against the risks of immunosuppression. Many 
patients with PIC have long periods without disease activity and may go into 
long-term remission, but in others these quiescent periods may be punctuated by 
explosive, sight-threatening episodes. Fourthly, the evidence base to support any 
one treatment strategy is weak. Prospective clinical trials in PIC are few in 
number, and most evidence is derived from uncontrolled series, expert opinion, 
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and personal experience. Challenges to the design and effective delivery of 
studies in PIC includes the rarity of the condition, controversy over the definition 
and classification of the disease, difficulties in defining robust outcome measures, 
and the highly variable natural history of the condition.  
Before discussing the evidence for specific therapies, it is worth noting two 
general principles for which there is consensus. First, that many patients with PIC 
have a good visual outcome, but that there is significant variation between 
patients. Second, that intervention is required in the following instances: (1) to 
treat new or active inflammatory ‘PIC’ lesions (particularly those threatening the 
fovea) and (2) to treat secondary CNV.(1) In addition the condition of the  fellow 
eye needs to be considered. Poor visual acuity in the fellow eye from a  previous 
presumed PIC episode would indicate a lower threshold to treat aggressively. 
Treatment options described include local and systemic corticosteroids, systemic 
immunomodulatory drugs, intravitreal vascular endothelial growth factor inhibitors 
(anti-VEGF), PDT, argon laser, and submacular surgery. Additionally 
combination therapy has been trialed in some cases.  
 
 
• Corticosteroids 
 
Corticosteroids have two potential roles in the management of PIC. First, they 
provide effective inhibition of the critical immune and inflammatory pathways that 
lead to the development of PIC lesions. Their rapid onset of action means that 
they are commonly used to control acute flares of disease. Second, they appear 
to have an anti-angiogenic role and may lead to regression of PIC-associated 
CNV, even in the absence of other treatments.(11, 26, 46, 53)  Levy et al. 
suggest that this effect may be in part via the anti-inflammatory effect of 
corticosteroids reducing endothelial proliferation in active CNV.(46) 
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Administration of corticosteroids in PIC may be systemic or local (periocular or 
intravitreal). There is insufficient evidence to recommend one mode of steroid 
delivery over another or to compare different steroid formulations. In the 
Gerstenblith survey 60% PIC patients reported that they had received treatment 
with systemic corticosteroids, 22% with intraocular corticosteroids and 10% with 
periocular corticosteroids.(30) 
Evidence for the effectiveness of corticosteroids in controlling inflammation in 
PIC comes mainly from case-reports and uncontrolled case series. Brueggeman 
et al. reported that the use of oral corticosteroids was associated with reduction 
in the number of choroidal PIC lesions; however, visual acuity did not change 
probably due to subfoveal scar formation.(11) The difficulties of evaluating 
efficacy of intervention based on retrospective non-randomized series is nicely 
illustrated by the series by Essex et al.(25) In 136 patients with PIC, treatment 
with corticosteroids was associated with a higher rate of developing CNV in 
normal fellow eyes, and treatment with immunosuppression was associated with 
a trend towards worse outcome.(25) We would agree with the report’s authors 
that this is almost certainly due to the selection bias inherent in these treatments 
being allocated to patients with more severe, active disease. 
Although not specific to PIC, a number of landmark trials provide evidence of the 
efficacy and safety of both intravitreal and systemic corticosteroids in controlling 
inflammation in those forms of uveitis that affect the posterior segment. The 
HURON study was a 26-week, prospective, multicenter, masked, randomized, 
sham-controlled clinical trial examined the effect of two strengths of 
dexamethasone intravitreal implant (both 0.35 and 0.70 mg) in posterior and 
intermediate uveitis and showed that there was a significant improvement in the 
degree of inflammation and visual acuity over a six month follow up with a single 
implant.(50) Retisert®, a longer-lasting fluocinolone acetonide implant, has also 
been trialed in these groups of patients. In a multicenter randomized control 
study reported by Pavesio et al. the implant was compared to standard of care 
therapy i.e. oral corticosteroids with or without other immunosuppressive drugs in 
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noninfectious posterior uveitis.(63) They found that eyes that received the 
implant experienced delayed onset of observed recurrence of uveitis (P<0.01) 
and a lower rate of recurrence of uveitis (18% vs. 64%; P<0.01) compared with 
control eyes. Adverse events frequently observed in implanted eyes included 
elevated intraocular pressure requiring surgery (18% eyes) and cataracts (88% 
phakic eyes), but no non-ocular adverse events. For comparison, cataracts 
occurred in 26% of control subjects.(63) The implant was also evaluated in the 
Multicentre Uveitis Steroid Treatment (MUST) trial, which observed similar safety 
profiles, but did not find a statistically significant difference in efficacy between 
the implant and standard of care. The authors make a point that the specific 
advantages and disadvantages in terms of adverse events identified should 
dictate selection between the alternative treatments in individual patients. (38) 
The effectiveness of corticosteroids in controlling PIC-associated CNV was 
reported  by Flaxel et al who noted that oral prednisolone improved or stabilized 
vision in 9 out of 10 eyes with PIC-associated CNV.(26) The rapidity of response 
is highlighted in the case-report by Levy et al in which an eye with PIC-
associated CNV recovered from 6/60 to 6/9 within 1 week after commencing a 
tapering dose of 60mg oral prednisolone.(46) They postulated that the use of 
corticosteroids might not alter outcome, but that it caused faster recovery of 
vision. 
 
 
B. Corticosteroid-sparing Immunosuppressants  
 
Treatment with corticosteroid-sparing immunosuppressant should be 
considered in patients who require maintenance therapy with corticosteroids 
to control their inflammation, particularly if the maintenance dose is greater 
than 7.5mg prednisolone per day or there are specific contra-indications for 
ongoing corticosteroid therapy. The evidence for these agents in PIC is very 
limited, but extensive safety data is available from their use in other ocular 
and non-ocular inflammatory conditions.  
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Mycophenolate mofetil (Cellcept®) is a commonly used anti-proliferative 
agent in ocular inflammatory disease.(29) Turkcuoglu et al. reported a series 
of 8 patients with PIC in which the frequency of recurrences was significantly 
lower after commencing mycophenolate mofetil based on a minimum of 12 
months post-treatment follow-up.(83) Evidence of its efficacy in ocular 
inflammation (not specific to PIC) is reported in the SITE study in which it 
was successful in controlling intraocular inflammation fully in 71% of patients 
at 1 year follow-up.(21) Galor et al.  previously found that mycophenolate 
mofetil was more effective than other antimetabolite treatments in achieving 
corticosteroid-sparing success in ocular inflammation.(29) 
 
Evidence for the use of other agents is mainly from case reports. Sirolimus 
(rapamycin) is a macrolide antibiotic that inhibits activation of T- and B-
lymphocytes. Nussenblatt et al. report on a young female patient with PIC-
related CNV who had had an adverse outcome in the first CNV-affected eye 
despite periocular corticosteroid injections and PDT treatment.(58) When 
she developed CNV in the second eye, she was treated with a 4 month 
course of oral rapamycin with angiographic cessation of leakage and 
stabilization of visual acuity over a follow-up period of 9 months. The use of 
interferon beta-1A is reported for a patient with multiple sclerosis (MS) and 
PIC-associated CNV who previously had multiple recurrences while on 
prednisone and methotrexate. The commencement of interferon for the 
patient’s MS was associated with cessation of relapses of inflammation and 
stabilization of the CNV with recovery of vision.(17) Treatment with 
thalidomide failed to prevent a recurrence of CNV in a 38-year-old patient 
with bilateral CNV.(33) 
 
• Anti-VEGF intravitreal therapy 
Without treatment, PIC-associated CNV tends to progress and may result in poor 
visual outcome; Brouzas et al. reported progression of lesion size in all cases of 
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a series of five eyes with PIC-associated CNV who did not receive treatment.(9) 
The success of anti-VEGF treatment in stabilizing vision in patients with CNV 
secondary to age-related macular degeneration (AMD) is well established and is 
illustrated by double-blind, multi-centered, randomized controlled trials.(75) There 
are far fewer studies evaluating the safety and efficacy of anti-VEGF therapy in 
CNV secondary to non-AMD conditions. Mansour et al. reported on a 
retrospective multicenter series of intravitreal bevacizumab in 99 eyes with 
inflammatory CNV of which 23 had PIC. Of PIC lesions most (61%) CNV were 
subfoveal.  The mean size was 1.1 Disc Diameters (DD). (52) Complete 
regression of CNV was seen in 83% cases with significant visual improvement at 
6 and 12 months.Zhang et al.  prospectively evaluated 12 eyes with PIC-related 
CNV treated with intravitreal bevacizumab and found that, at 12 months of follow-
up, all eyes had stable or improved vision, with 75% showing an improvement of 
visual acuity of at least two lines. (88) 
Cornish et al. reported on a retrospective series of 9 patients with PIC- 
associated CNV, six of whom were treated with bevacizumab and three who 
were treated with ranibizumab. At final follow-up visual acuity had stabilized or 
improved in eight patients, with deterioration in one.(20) 
A series from Chan et al. included 4 eyes with PIC-related CNV in their series 
and after a series of three injections of bevacizumab at four-weekly intervals, 
there were good visual and anatomical results; FA showed absence of CNV 
leakage at three months and no recurrence at six months in all cases, with 
improvement of visual acuity of between 1 and 5 Snellen lines.(14) Rouvas et al. 
have reported on a retrospective case series evaluating treatment with 
ranibizumab for inflammatory CNV in 16 eyes  of which 5 had PIC-associated 
CNV. The PIC subset experienced a mean gain in vision of 21 ETDRS letters 
using a mean 2.2 injections; with a mean follow-up of 87 weeks. All eyes (PIC 
and non-PIC) showed regression of CNV.(71)A positive role of intravitreal 
ranibizumab was also found by Menezo et al in a retrospective study of 10 
patients with PIC-associated CNV where 9 of the 10 eyes achieved stabilisation 
or improvement in their vision.(54) 
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 It should be recognized, however, that the angiogenic drive is complex, and anti-
VEGF treatment alone will not stabilize all cases. Pachydaki et al. have proposed 
that targeting platelet –derived growth factor in addition to VEGF may be required 
in treatment-resistant cases, as well as immunomodulatory treatment to reduce 
choroidal lymphocytic infiltration.(60) 
 
• Photodynamic therapy 
Verteporfin photodynamic therapy (PDT) has been used as a safe treatment 
modality to stabilize and improve vision in PIC-associated and other 
inflammatory CNV for subfoveal, extrafoveal and juxtafoveal 
lesions.(9,85,43,49,16,68) Some studies have reported higher recurrence 
rates of CNV after PDT treatment; it is not yet clear if this is a real difference 
or arises due to differences in follow-up duration.(78, 19) 
 
Coco et al. reported on eight patients with PIC-associated CNV (six 
juxatfoveal, two subfoveal) with mean follow-up of 23 months. Four of the 
patients had had previous or ongoing corticosteroid treatment with or without 
other immunosuppressants. All showed angiographic cessation of leakage. 
Visual acuity improved in five eyes (range +1 to +7 lines), but declined in 
three. One patient developed a new CNV within a few days of PDT, and late 
recurrences were seen in two of the three patients with extended follow-
up.(19)  
 
Leslie et al. reported on four patients with PIC-associated CNV who had not 
responded to prednisolone with or without a second-line agent.  Subsequent 
treatment with PDT resulted in visual improvement in all four cases at 10 
months follow-up.(43) There are also a number of series reporting the use of 
PDT in inflammatory CNV, but which do not provide the sub-group data to 
assess the effect specifically on PIC-associated CNV.(85, 64)The most 
relevant of these is the series by Postelmans et al who reported on PDT 
treatment in 16 eyes with subfoveal classic CNV associated with PIC or 
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‘pseudo-POHS’ (i.e. POHS-like, but in a non-endemic area) and noted 
stabilization or improvement of VA in 13/16 cases.(64) The positive 
outcomes in these series and of numerous PIC-specific case-reports are 
generally taken as further indirect evidence to support the use of PDT at 
least as an adjunctive therapy in PIC.(16) 
 
• PDT Combined with Corticosteroids  
 
PDT has been combined with both systemic and local corticosteroid therapy. 
It has been argued that the vaso-occlusive effect of PDT synergizes with the 
vasostatic and anti-inflammatory effect of systemic corticosteroids.(27) Fong 
et al. performed a prospective interventional case-series of five patients with 
subfoveal CNV secondary to PIC initially started on oral prednisolone (1 
mg/kg body weight/day) followed by PDT treatment five days later with a 
mean 12 month follow-up who showed a mean improvement in vision of nine 
letters.(27) 
 
A nonrandomized, open-label, interventional prospective study investigated 
the success of combined treatment with intravitreal triamcinolone acetonide 
(IVTA) (4mg/0.1 mL) and PDT in PIC-associated CNV (n=4) and idiopathic 
CNV (n=10)  (78). At one year the CNV was inactive in all cases with 13/14 
eyes had stable or improved vision (mean improvement of 3.2 lines), but 
with one eye developing submacular fibrosis that resulted in a three line loss 
of VA. This patient had the largest CNVM, and it may be that PDT is less 
effective for larger CNVM.(13) 
 
• Laser photocoagulation 
Brown et al. reported laser photocoagulation in two patients with extra-foveal 
CNV membrane who improved and retained vision to 20/40.(10) Since the 
advent of first PDT and then anti-VEGF therapy, this treatment modality has 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
been abandoned as it can result in blinding scotomas and is thus particularly 
unsuitable for the predominantly centrally located macular CNV seen in PIC. 
 
• Submacular surgery 
 
Several series have reported successful surgical treatment of subfoveal CNV in 
PIC, although this has been superseded by PDT and then anti-VEGF therapy. 
Olsen at al. reported on six eyes with subfoveal CNV in PIC, with successful 
surgical excision and improvement of visual acuity in all cases, but high rates of 
recurrence (4/6 eyes).(59) Essex et al reported on surgical excision in 21 PIC-
associated subfoveal CNV as part of a series of 52 non-AMD eyes. The overall 
frequency of recurrent CNV was 31% following excision with a median time to 
recurrence of 27 weeks and additional risks of lens damage and post-operative 
retinal detachment are described.(23) Ehlers et al. reported on macular 
translocation surgery in a series of 16 eyes with non-AMD macular pathology of 
which two cases had PIC and three had POHS. Overall, the visual acuity 
improved by more than 3 lines in 38% of patients with a final visual acuity of 
better or equal to 20/50 in 31% of patients over a mean follow up period of 28 
months.(22) In summary, even when initially successful, such surgery in PIC was 
associated with high rates of recurrence and should be avoided. 
VII. PIC and pregnancy 
Pregnancy has been associated with the development or recurrence of CNV , 
being reported secondary to PIC, POHS or even in the absence of pre-existing 
inflammation.(66, 76) It is likely that this arises from elevated levels of angiogenic 
factors such as VEGF and placental growth factor (PIGF). VEGF levels increase 
during the first trimester and then decline (47), whereas PlGF increase steadily 
throughout pregnancy. (42) 
Many immune conditions improve during pregnancy as a result of 
immunoregulation for the protection of the fetus; however, Rao et al. report a 
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case of exacerbation of choroiditis with development of PIC-associated CNV in 
the first trimester of pregnancy.(66)Sim et al. described three women with PIC-
associated CNV arising during pregnancy and highlight specific management 
issues, including the avoidance of FFA. These cases received either no 
treatment, IVTA or sub-Tenon triamcinolone acetonide (STTA). All had resolution 
of subretinal fluid and stabilization or recovery of vision. A number of small case-
series report on successful outcomes of the use of anti-VEGF therapy in 
pregnancy.(76) Tarantola report on the use of bevacizumab in four patients with 
inflammatory CNV during pregnancy, with improvement in visual acuity in all 
patients and delivery of healthy infants.(81) Rosen et al.  report a young pregnant 
female with PIC-associated CNV who was treated with PDT at 1-2 weeks 
gestation and a single treatment of bevacizumab at 3 months gestation. There 
was recovery of vision, stabilization of the CNV on OCT assessment, and 
delivery of a healthy infant. (69)The use of any treatment during pregnancy 
should be discussed in detail with the patient and with advice from the patient’s 
obstetrician to minimize the potential risks to mother and child. 
 
VIII. Prognosis  
The visual outcome in PIC depends on the location of the lesions, and whether 
they are complicated by the formation of CNV. Many patients do well, with visual 
acuity of 20/40 or better; however, approximately one fifth will end up with a VA 
of <20/200 mainly from development of CNV and subretinal fibrosis.(10,59,86)  
The risk of CNV is higher in PIC than other posterior and panuveitic conditions 
The presence of active inflammation and previous CNV in the other eye increase 
the risk.(6,30, 62)  The rate of CNV has been reported to be 17-75% in patients 
with PIC, depending on size of case series and variable follow-up, but in their 
large series, Essex et al. report a cohort of 74 eyes with PIC lesions, but no CNV 
at baseline, in which CNV developed in 22%, new PIC lesions in 12%, and no 
disease in 66% (mean follow-up of 4.5 years). Of those that developed CNV, 
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26% of these eyes had a final VA of less than 20/200.(25) In the Gerstenblith 
survey, 69% of 77 patients reported that they had experienced CNV and 56% 
had developed subretinal fibrosis.(30)    
 
IX. Further research and Patient Engagement 
Despite the advances in imaging that enable unparalleled visualization of the 
onset and development of PIC lesions, the etiology of PIC remains unknown, the 
indications for treatment are uncertain, and high-level evidence to support a 
treatment strategy is lacking. As discussed earlier, conducting randomized 
controlled trials of treatments for PIC is challenging, however there is a need for 
this higher level evidence. We would urge the community of clinical experts and 
patients to work together to undertake the studies that will address the 
challenges of disease stratification to decide which patients may benefit from 
maintenance treatment and who may safely be observed and optimal treatment 
(efficacy and safety).  
Research priorities should be informed by patient experience of their disease, 
such as achieved through the James Lind alliance or engagement with patient 
support societies. Surveys through patient support websites such as conducted 
by Gerstenblith are valuable, but need to be extended to assess quality of life 
issues.(30) Although data is lacking for patients with PIC, research into patients 
with similar conditions has highlighted the need to include patient reported 
outcome measures and quality of life measures alongside traditional clinical 
measures of the disease.(41) A PIC-specific patient-reported outcome measure 
would be ideal (as has been developed for birdshot chorioretinopathy),(5) but 
until such a tool is developed standard instruments such as the National Eye 
Institute Visual Function Questionnaire (VFQ)-25 should be used to assess 
impact of disease and effect of treatment.  
X. Conclusions 
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In summary, PIC is a rare, idiopathic inflammatory multifocal chorioretinopathy 
with a variable outcome ranging from complete spontaneous recovery to bilateral 
severe visual loss. Detection and monitoring have been greatly facilitated by 
modern scanning techniques, especially OCT and autofluorescence imaging, and 
may be enhanced by co-registration of sequential images to detect change over 
time. Our concern, however, is that even with these advances there are many 
occasions when this condition is not recognized at initial presentation, resulting in 
patients presenting late to a specialist center with visually significant disease. 
Depending on the course of disease and nature of complications, appropriate 
treatment may range from observation to systemic immunosuppression and anti-
angiogenic therapies. Extrafoveal disease is associated with better visual 
prognosis, and in some instances it may be appropriate to initially observe such 
cases. Active inflammation, particularly in the presence of sight-threatening 
sequelae, is an indication for immunosuppression which may range from local 
corticosteroids to combinations of systemic corticosteroids and second-line 
steroid-sparing agents. CNV may be responsive to immunosuppression alone, 
but is often treated effectively with anti-VEGF therapy. PDT appears to be 
effective, but is associated with a high rate of recurrence. PIC is a challenging 
condition in which treatment has to be tailored to the patient’s individual 
circumstances, the extent of disease, and the risk of progression. All parties have 
to accept that the prognosis is uncertain. 
XI. Method of Literature Search 
The original literature search was undertaken in January 2016, with an updated 
search conducted in May 2016 to identify any ‘late-breaking’ articles. The 
following databases were searched: Medline, EMBASE, and the Cochrane 
Library with a date limit of 1946 to the present for Medline, 1974 to present for 
EMBASE and no date restriction for Cochrane. The search used the following 
terms: “Punctate inner choroidopathy”, ‘Punctate inner choroditis”, and “multifocal 
inner choroiditis”. Papers were then categorized according to their relevance to 
the following section headings (papers could contribute to multiple sections): 
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‘epidemiology’, ‘demographics’, ‘pathogenenesis’, ‘clinical description’, 
‘diagnosis’, ‘ancillary tests’, ‘differential diagnoses’, ‘management’, ‘PIC in 
pregnanacy’ and ‘prognosis’. All relevant clinical studies were considered but 
were weighted according to their level of evidence, with well-designed 
randomized prospective clinical trials ranked highest and case-reports ranked 
lowest; case-reports were generally excluded from the final review unless they 
were considered to provide unique insights not evident from higher level studies. 
Articles which did not present primary data (such as reviews and expert opinion) 
were also considered and were included if they provided original insights into the 
condition, based on appropriate published primary data. Articles in languages 
other than English were also considered if they provided an English abstract 
which could be used for screening their relevance to decide whether translation 
of the full article was required.   
 
  
  
Figure Legends: 
 
Figure 1. Color fundus photography of right (A), and left (B) eyes, demonstrating 
the characteristic features of punctate inner choroidopathy (PIC) in a 39-year-old, 
white, myopic woman. This woman has a 10 year history of the disease and had 
presented again with new onset photopsia and scotomas. This patient explicitly 
and repeatedly declined all treatment so the subsequent progression reflects the 
natural history of her disease. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Figure 2. Fundus autofluorescence imaging (Blue-Peak autofluorescence, 
Heidelberg Engineering, Germany) of the 39 year old woman described in Figure 
1. The left image (A) is taken at the time of her representation with acute 
symptoms and demonstrates multiple hypofluorescent punctate inner 
choroidopathy (PIC) lesions with surrounding zones of hyperautofluorescence. 
The right image (B) was taken three years previously at a time when the patient 
was asymptomatic and the disease was considered quiescent.  
 
Figure 3. Optical coherence tomography (OCT) imaging (Spectralis, Heidelberg 
Engineering, Germany) of the 39 year old woman described in Figure 1. The top 
(A) and middle images (B) are taken at the time of her representation with acute 
symptoms and demonstrates prominent choroidal thickening with choroidal 
hyperreflective foci, and the outer retinal involvement of multiple PIC lesions. The 
bottom image (C) was taken three years previously at a time when the patient 
was asymptomatic and the disease was considered quiescent. It demonstrates a 
relatively normal choroidal appearance. 
Figure 4. Optical coherence tomography (OCT) imaging (A) (Spectralis, 
Heidelberg Engineering, Germany) of a 39 year old myopic man who presented 
with reduced vision in his right eye and was diagnosed with punctate inner 
choroidopathy (PIC). OCT angiography was performed (Optovue AngioVue, 
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United States) and clearly delineated a choroidal neovascular membrane (B), 
without the need for fluorescein angiography.  
 
 
  
  
List of abbreviations 
 
Punctate inner choroidopathy (PIC) 
Age-related macular degeneration (AMD) 
Photodynamic therapy (PDT) 
Choroidal neovascularization (CNV) 
Anti- vascular endothelial growth factor (Anti-VEGF) 
Fluorescein angiography (FA) 
Indocyanine green angiography (ICG) 
Optical coherence tomography (OCT) 
Spectral domain OCT (SD-OCT) 
Enhanced depth imaging OCT (EDI – OCT) 
Multifocal choroiditis and panuveitis (MCP) 
Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) 
Presumed ocular histoplasmosis syndrome (POHS) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Diffuse subretinal fibrosis syndrome (DSFS) 
Birdshot chorioretinopathy (BCR)  
Multiple evanescent white dot syndrome (MEWDS) 
Intravitreal triamcinolone acetate (IVTA) 
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